ライフサイエンスコーパス: hepatic failure

1 nting and treating viral and toxic fulminant hepatic failure.

2 atients with acetaminophen-induced fulminant hepatic failure.

3 flammatory response, which accompanies acute hepatic failure.

4 n developed to support patients in fulminant hepatic failure.

5 progressive hepatic fibrosis, cirrhosis and hepatic failure.

6 ients awaiting transplantation for fulminant hepatic failure.

7 Rosiglitazone may be associated with hepatic failure.

8 nt of intracranial hypertension in fulminant hepatic failure.

9 est results to rapidly progressive and fatal hepatic failure.

10 yptogenic cirrhosis and idiopathic fulminant hepatic failure.

11 treatment of organic acidemias and fulminant hepatic failure.

12 ncluding cryptogenic cirrhosis and fulminant hepatic failure.

13 efined selection, particularly for fulminant hepatic failure.

14 develop cirrhosis, portal hypertension, and hepatic failure.

15 sfully performed in a patient with fulminant hepatic failure.

16 halopathy but appears unchanged in fulminant hepatic failure.

17 encephalopathy and brain edema in fulminant hepatic failure.

18 r the death rate from sepsis and progressive hepatic failure.

19 function of hepatic allografts and fulminant hepatic failure.

20 otransplantation for patients with fulminant hepatic failure.

21 d to acute hepatitis and rarely to fulminant hepatic failure.

22 in lymph nodes rescued the mice from lethal hepatic failure.

23 isease that can be severe resulting in acute hepatic failure.

24 brain injury, ischemic stroke, and fulminant hepatic failure.

25 n improve liver function in a mouse model of hepatic failure.

26 of normal but almost never causes fulminant hepatic failure.

27 inical strategies for the treatment of human hepatic failure.

28 s to steatosis with mitochondrial injury and hepatic failure.

29 able, minimally invasive form of therapy for hepatic failure.

30 complications and mortality associated with hepatic failure.

31 for isolated, rapidly progressive infantile hepatic failure.

32 itonitis, hepatorenal syndrome, or fulminant hepatic failure.

33 odynamic instability or significant renal or hepatic failure.

34 s leading to liver transplantation for acute hepatic failure.

35 one of the few treatable causes of fulminant hepatic failure.

36 mild elevations in liver tests to fulminant hepatic failure.

37 ival in patients with fulminant/subfulminant hepatic failure.

38 r coronary bypass surgery and the other from hepatic failure.

39 resented with acute BCS leading to fulminant hepatic failure.

40 o liver transplantation for the treatment of hepatic failure.

41 gulopathy, hyperbilirubinemia, and fulminant hepatic failure.

42 epatocytes is a seminal feature of fulminant hepatic failure.

43 ntive lamivudine group developed HBV-related hepatic failure (0 of 108 patients vs. 21 of 162 patient

44 of 11) of patients with idiopathic fulminant hepatic failure, 18% (2 of 11) of patients with a histor

45 s (3%), fatigue (3%), gastric stenosis (3%), hepatic failure (3%), liver abscesses (3%), paroxysmal a

46 under 5 years of age, including 16 for acute hepatic failure, 46 for chronic liver disease, and 11 re

47 Eight (33%) patients with fulminant hepatic failure, 97 (66%) patients with chronic liver di

48 lantation if they have evidence of fulminant hepatic failure, a life-threatening systemic complicatio

49 available to salvage patients who developed hepatic failure after a prior surgical procedure.

50 previously reported as a cause for fulminant hepatic failure after liver transplantation.

51 on at concentrations commonly encountered in hepatic failure, an event preceding the suppression of i

52 cation to prevent amplification of fulminant hepatic failure and acetaminophen-induced hepatotoxicity

53 eding, as well as in patients with fulminant hepatic failure and alcoholic hepatitis.

54 inous clinical course leading to progressive hepatic failure and death if liver transplantation is no

55 ific antibodies into mice leads to fulminant hepatic failure and death.

56 unts for 20-40% of all instances of clinical hepatic failure and is a common reason for withdrawal of

57 Patients with fulminant/subfulminant hepatic failure and primary nonfunction following liver

58 inning to acknowledge subgroups of fulminant hepatic failure and properly randomize therapy.

59 Patient 2 developed subfulminant hepatic failure and required liver transplantation.

60 ity is commonly seen at imaging in fulminant hepatic failure and usually reflects a combination of al

61 ll 4 patients developed clinical features of hepatic failure and were retransplanted.

62 ransferred to our institution with fulminant hepatic failure and worsening hepatic encephalopathy of

63 plications of acute liver failure (fulminant hepatic failure) and a major cause of death in this cond

64 ting in failure to thrive, hepatomegaly, and hepatic failure, and an average life expectancy of less

65 c regression, mortality predictors were: MV, hepatic failure, and cardiovascular failure for the grou

66 ation score, vasopressor use, serum albumin, hepatic failure, and coagulopathy.

67 mmune hepatitis (AIH) can lead to cirrhosis, hepatic failure, and death.

68 ces, including the development of cirrhosis, hepatic failure, and hepatocellular carcinoma.

69 ver disease that can develop into cirrhosis, hepatic failure, and hepatocellular carcinoma.

70 in settings such as traumatic brain injury, hepatic failure, and migraine headache has yet to be ful

71 ere hospitalized, four developed evidence of hepatic failure, and one died.

72 cryptogenic cirrhosis, idiopathic fulminant hepatic failure, and patients with other forms of advanc

73 ere was a trend for UNOS status 1, fulminant hepatic failure, and presence of LPD to be associated wi

74 s of sudden infant death syndrome, fulminant hepatic failure, and severe complications during pregnan

75 UNOS status 1, fulminant hepatic failure, and the development of Epstein-Barr vir

76 the high levels of ammonia that circulate in hepatic failure appear to be important.

77 who die from paracetamol overdose fulminant hepatic failure as accurately as King's College criteria

78 cases, as well as in patients with fulminant hepatic failure at high risk for mortality who have not

79 nderwent liver transplantation for fulminant hepatic failure at our institution during a 5-year perio

80 Extended liver resection leads to hepatic failure because of a small remnant liver volume.

81 lantation is associated with acute fulminant hepatic failure, biliary tract necrosis and leaks, or re

82 ause of morbidity and mortality in fulminant hepatic failure but has not been well documented as a co

83 olongs survival during LPS- and GalN-induced hepatic failure by temporarily protecting hepatocytes ag

84 lows: a) chronic liver failure; b) fulminant hepatic failure; c) patients immediately status post-ort

85 T for the BMT group (39% overall mortality); hepatic failure, cardiovascular failure, and persistent

86 Excluding acute hepatic failure caused by drugs, the etiology of fulmina

87 reditary tyrosinemia type I (HT1) results in hepatic failure, cirrhosis, and hepatocellular carcinoma

88 use of vasopressors/inotropes, pancreatitis, hepatic failure/cirrhosis with ascites, gastrointestinal

89 igh mortality rate associated with fulminant hepatic failure combined with the limited availability o

90 ients, including one who developed fulminant hepatic failure complicated by cerebral edema, were taki

91 After 21 days of rosiglitazone therapy, hepatic failure developed.

92 l endothelium and portal tracts of fulminant hepatic failure explants, whereas there were minimal cha

93 Patients diagnosed with fulminant hepatic failure face high mortality rates.

94 of AA included non-A, non-B, non-C fulminant hepatic failure (FHF) (3 patients), graft-versus-host di

95 During human fulminant hepatic failure (FHF) circulating levels of most hemosta

96 r support system for patients with fulminant hepatic failure (FHF) continues to be unmet.

97 Patients with fulminant hepatic failure (FHF) die with brain edema, exhibiting a

98 e of an adult female who developed fulminant hepatic failure (FHF) during the second trimester of pre

99 Fulminant hepatic failure (FHF) in humans produces a bleeding diat

100 thy residual liver mass, otherwise fulminant hepatic failure (FHF) may arise.

101 Patients with fulminant hepatic failure (FHF) often die awaiting liver transplan

102 The effect of RI on patients with fulminant hepatic failure (FHF) or chronic liver disease (cirrhosi

103 cible experimental animal model of fulminant hepatic failure (FHF) resembling the clinical condition

104 ients who received transplants for fulminant hepatic failure (FHF) were stratified separately from th

105 tic metabolic pathways affected by fulminant hepatic failure (FHF) would help develop nutritional sup

106 nly proven effective treatment for fulminant hepatic failure (FHF), but its use is limited because of

107 OLT) is an effective treatment for fulminant hepatic failure (FHF), but postOLT mortality is higher f

108 ogic agents in non-A, non-B (NANB) fulminant hepatic failure (FHF), but the frequency of infection wi

109 roup 1 (n = 18) were patients with fulminant hepatic failure (FHF), in group 2 (n = 3) were patients

110 ic liver transplantation (OLT) for fulminant hepatic failure (FHF), some patients develop cerebral in

111 hepatic biliary atresia (EHBA) and fulminant hepatic failure (FHF).

112 logical role of TTV in cryptogenic fulminant hepatic failure (FHF).

113 r transplantation in patients with fulminant hepatic failure (FHF).

114 ccurs in half of all children with fulminant hepatic failure (FHF).

115 involve the liver but rarely cause fulminant hepatic failure (FHF).

116 support for comatose patients with fulminant hepatic failure for up to 5 days.

117 Patients dying of fulminant hepatic failure, for whom no alternative therapy is avai

118 A 25-year-old man presented with fulminant hepatic failure from an unusual peripheral T cell lympho

119 of liver dysfunction in a rat model of acute hepatic failure generated by d-galactosamine (GalN) inje

120 ture was markedly increased in the fulminant hepatic failure group (mean energy expenditure, 4.05 [SD

121 Hepatic failure has been treated successfully with clini

122 rbidity (symptoms, cirrhosis) and mortality (hepatic failure, HCC) are modest in frequency.

123 utual relationships, and those, if any, with hepatic failure/hepatic encephalopathy.

124 Clinical consequences include hepatic failure, hepatocellular carcinoma, diabetes, car

125 ntal protocol of LPS-induced acute fulminant hepatic failure (i.p. injection of low dose of LPS in co

126 ioartificial liver device to treat fulminant hepatic failure improved animal survival, thereby unders

127 patocyte-like cells rescued lethal fulminant hepatic failure in a nonobese diabetic severe combined i

128 HC-TN (genotype 1a), which caused fulminant hepatic failure in a patient and, subsequently, severe h

129 a known risk for hepatoxicity, and leads to hepatic failure in a small subset of patients.

130 (LPS) and D-galactosamine (GalN) results in hepatic failure in mice.

131 ion were biliary atresia in seven, fulminant hepatic failure in six, chronic rejection in seven, and

132 limiting liver disease that causes fulminant hepatic failure in specific high-risk groups only.

133 cebo group, including two patients (1%) with hepatic failure in the placebo group.

134 ed the effect of KGF on LPS and GalN-induced hepatic failure in vivo and on TNF- and ActD-induced hep

135 d in the differential diagnosis of fulminant hepatic failure in young patients who show no evidence o

136 Incidence of hepatic failure increases with the hospital length of st

137 The management of patients with fulminant hepatic failure is a major clinical endeavor.

138 Hepatic failure is commonly associated with anemia, whic

139 The pathogenesis of brain edema in fulminant hepatic failure is still unresolved.

140 ) is both the leading cause of cirrhosis and hepatic failure leading to liver transplantation and a c

141 as become the leading cause of cirrhosis and hepatic failure leading to OLT.

142 prevented endotoxin-induced lethal fulminant hepatic failure, leading to dramatically enhanced surviv

143 -0.945; p = .023) whereas hepatic cirrhosis, hepatic failure, leukemia, multiple myeloma, transfer fr

144 At least in theory, anemia during hepatic failure may result from accelerated clearance of

145 n plasma and brain glutamine associated with hepatic failure may, by increasing brain GABA release, p

146 Two hamster models of hepatic failure, namely functional hepatectomy (HepX), a

147 Multivariate analysis showed hepatic failure [odds ratio (OR), 11.2], renal failure (

148 was a 13-year-old boy with acute, fulminant hepatic failure of unknown etiology who underwent cadave

149 d in the differential diagnosis of fulminant hepatic failure of unknown pathogenesis.

150 No fulminant hepatic failure or death was observed.

151 ed into dengue encephalopathy (eg, caused by hepatic failure or metabolic disorders), encephalitis (c

152 in developing approaches to the treatment of hepatic failure or more broadly to the treatment of comp

153 Patients were without significant renal or hepatic failure or shock at entry.

154 ar disease (OR = 2.2), renal (OR = 3.2), and hepatic failure (OR = 10.8) as independent predictors of

155 However, survival in fulminant/subfulminant hepatic failure patients was significantly higher in the

156 This higher mortality is because of hepatic failure, possibly a result of excessive diminuti

157 ed with an increased risk of bleeding: acute hepatic failure, prolonged duration of nasogastric tube

158 cute renal failure resulting from cardiac or hepatic failure, prolonged surgery, and nephrotoxic effe

159 patient died in early childhood of fulminant hepatic failure, refractory epilepsy, lactic acidemia, a

160 re related to myocardial infarction, stroke, hepatic failure, renal failure or sepsis.

161 nt for dilated cardiomyopathy, the patient's hepatic failure resolved and she made a full recovery.

162 A 28-year-old male with fulminant hepatic failure secondary to hepatitis B was referred to

163 Adjusted for age, hepatic failure, sepsis, thrombocytopenia, blood urea ni

164 Patients with fulminant hepatic failure should be stabilized and transferred to

165 Candidates with fulminant hepatic failure (Status-1A) receive the highest priority

166 Other causes of hepatic failure, such as viruses and toxins, were exclud

167 CV infection has become the leading cause of hepatic failure that requires OLT.

168 sms may account for brain edema in fulminant hepatic failure: the osmotic effects of brain glutamine,

169 . 11.0+/-4.7, P=0.01) and fewer days free of hepatic failure to day 14 (10.8+/-5.0 vs. 11.8+/-4.3, P=

170 ation may be used in patients with fulminant hepatic failure to facilitate fluid removal and circulat

171 ease ranging from acute (including fulminant hepatic failure) to chronic hepatitis, cirrhosis, and he

172 Z scores greater than -2.0 at OLT, fulminant hepatic failure, tumor, and postOLT complications causin

173 sing cholangitis, cystic fibrosis, fulminant hepatic failure, tyrosinemia, and chronic rejection.

174 Four patients with fulminant hepatic failure underwent extracorporeal liver perfusion

175 agnosis of tumor, (v) diagnosis of fulminant hepatic failure, (vi) retransplantation, (vii) graft dis

176 Acetaminophen overdose causes massive hepatic failure via mechanisms involving glutathione dep

177 Ten patients with fulminant hepatic failure were excluded from the study, leaving 99

178 asogastric intubation, alcoholism, and acute hepatic failure were found to be independently correlate

179 h during the first months of life because of hepatic failure, whereas a chronic form leads to gradual

180 -induced rat model of irreversible and fatal hepatic failure, which also exhibits terminal changes in

181 r without infections, and cardiac, renal, or hepatic failure, which are common features of glycosylat

182 lthough rare, HSV-1 can also cause fulminant hepatic failure, which is often fatal.

183 of ECMO, and patients who developed renal or hepatic failure while on ECMO.

184 ld be considered for patients with fulminant hepatic failure who are appropriate transplant candidate

185 can aid in early detection of patients with hepatic failure who are unable to appropriately metaboli

186 ffering from acetaminophen-induced fulminant hepatic failure who were sedated, paralyzed, and mechani

187 sickle cell disease, who developed fulminant hepatic failure with subsequent extreme hyperbilirubinem

188 Patients meeting criteria for fulminant hepatic failure without acetaminophen toxicity (FHF-NA,

189 hunt group 1 have died of late postoperative hepatic failure without benefit of liver transplantation